Patients in Situation of Last Days of Their LifeCUIDARCUDECANCT07446673
Evaluation of CUDECA Cui-DAR Plan in People With Oncological and Non-oncological Diseases in the Last Days of Their Lives (CUIDARCUDECA)
An observational study of Patients in Situation of Last Days of Their Life and Oncological and no Onoclogical Disease, run by Cudeca Hospice Foundation at 3 sites in Spain.
Trial summary
Cudeca, an independent non-profit organization located in Malaga (Spain), treats patients with advanced and terminal disease. It has developed Cui-DAR Cudeca plan, a care plan for the care of patients in situations of last days of thier live that integrates in a single document, all the assessments and… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Patients in Situation of Last Days of Their Life, Oncological and no Onoclogical Disease
- What is being tested?
- Care Plan Cui-dar CUdeca
- How many people
- 348 participants
- Where
- 3 sitesSpain
- Study dates
- 27 Jan 2022to 20 Feb 2026
- How long will I take part?
- 3 Days
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients in the last days of life
Who may be able to join
- Acceptance to participate in the study by signing the informed consent.
- Patients in the last days of life who die in Cudeca Foundation and who was cared under Cui-DAR Cudeca Plan during data collection period.
- Patients in the last days of life who die in others Palliative care Units Cudeca Foundation and who was cared under Cui-DAR Cudeca Plan durging data collection period.
Who cannot join
- No acceptance to participate in the study by signing the informed consent.
- Patients in the last days of life who die in Cudeca Foundation and who wasn,t cared under Cui-DAR Cudeca Plan during data collection period.
- Pacients
Trial locations and contacts
3 sites in 1 country.
Spain3 sites
Instituto Catalan de Oncología
Barcelona, Barcelona
Fundación CUDECA
Benalmádena, Málaga, 29631
Hospital San Juan de Dios
Pamplona, Navarre
About this study
Official title: Validation and Evaluation of the CUDECA Cui-DAR Plan in People With Oncological and Non-oncological Diseases in the Last Days of Their Lives (CUIDARCUDECA)
Cudeca, an independent non-profit organization located in Malaga (Spain), treats patients with advanced and terminal disease. It has developed Cui-DAR Cudeca plan, a care plan for the care of patients in situations of last days of thier live that integrates in a single document, all the assessments and multidisciplinary actions necessary, from the beginning of last days situation, to the care after death. The objective of the study is to evaluate the validity and effectiveness of the Cui-DAR CUDECA Plan in people in a situation of last days compared to conventional care in the assessment of symptoms and signs.
Read the detailed description
Cudeca, an independent non-profit organization located in Malaga (Spain), treats patients with advanced and terminal disease. It has developed Cui-DAR Cudeca plan, a care plan for the care of patients in situations of last days of thier live that integrates in a single document, all the assessments and multidisciplinary actions necessary, from the beginning of last days situation, to the care after death. It is based on the Liverpool Care Pathway for the Dying Patient created by the Royal Liverpool University Hospital. The objective of the study is to evaluate the validity and effectiveness of the Cui-DAR CUDECA Plan in people in a situation of last days compared to conventional care in the assessment of symptoms and signs. The intervention group will be the patients in the last days of their illness treated at the Cudeca Center with the Cui-DAR Cudeca Plan and those of the control group those treated and deceased in the Palliative Care Unit of the Catalan Institute of Oncology of L'Hospitalet de Llobregat, located in the Duran i Reynals Hospital, which works together with the University Hospital of Bellvitge (Barcelona) and the patients treated in the Palliative Care Unit of San Juan de Dios Hospital in Pamplona (Navarra). In all groups, it will be assessed whether the quality standards recommended by the National Institute for Health and Care Excellence are met: "Care of dying adults in the last days of life", referring to the individualization of care, the anticipatory prescription of drugs and the control of hydration.
Null hypothesis (H0) that will be subjected to contrast in this study is that there are no differences in the assessment of symptoms and signs in patients in a situation of last days, regardless of whether the Cui-DAR CUDECA Plan is applied or not. Piloting will be done on a small sample of patients treated in Hospitalization Unit of CUDECA center.
For the sample calculation, results of national report on the care of people in a situation of imminent death in England have been taken into account.
Authorization of the Ethics Committee of the Costa del Sol District will be requested. The ethical principles established for research on human beings in the Declaration of Helsinki shall be maintained at all times.
Clinical data shall be kept segregated from identification data by means of an alphanumeric code. All registrations will be made respecting the precepts established in the current legislation on the protection of personal data.
- Being tested
- Care Plan Cui-dar CUdeca
- Keywords
- palliative care, last days of live, care plan, sympton control
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Care Plan Cui-dar CUdecaOther
Attend to the patient in the last days of their life with the CUi-DAR care plan
| Study group | Role | What they receive |
|---|---|---|
| Patients who died in the Hospitalization Unit of the Cudeca Foundation (Benalmádena, Málaga,Spain) | Patients in the last days of their illness who die treated in Cudeca,s Inpatient Unit attended with a specific care plan at this situation (Cui-DAR CUDECA Plan) Receives: Other: Care Plan Cui-dar CUdeca | |
| Patients who died in the Catalan Institute of Oncology hospital (Barcelona, Spain) | Patients in the last days of their illness who die treated in the Inpatient Unit of Catalan Institute of Oncology (L'Hospitalet de Llobregat ,Barcelona, España). No intervention. | |
| Patients who died in the Inpatient Unit of San Juan de Dios Hospital (Pamplona, Navarra, Spain) | Patients in the last days of their illness who die treated in he Inpatient Unit of San Juan de Dios hospital (Pamplona, Navarra, Spain). No intervention. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Number of patients with oncological and non-oncological diseases who are at the end of their lives and have been evaluated with the CUDECA Cui-DAR Plan for the care of symptoms and signs.
Patients with oncological and non-oncological diseases who die in the Cudeca Foundation Hospitalisation Unit attended with the CUi-DAR Cudeca Plan.
Measured: Through study completion, an average of 12 months
Secondary outcomes (4)
Number of patients with oncological and non-oncological diseases who has individualised care plans in the last days of life.
Number of patients with oncological and non-oncological diseases whose medical records indicate that they are in their final days, whose signs and symptoms are assessed, and who have an updated care plan that has been discussed with the patient and their family.
Measured: Through study completion, an average of 3 months
Number of patients with oncological and non-oncological diseases who are at the end of their lives and have been given an advance prescription for medication.
Number of patients with oncological and non-oncological diseases whose medical records indicate that they have been assessed for their prescription needs for symptoms that may arise in the final days of life and for anticipatory medications with individualised indications for use, dosage, and route of administration.
Measured: Through study completion, an average of 3 months
Number of patients with oncological and non-oncological diseases with daily assessment of hydration at the end of life
Number of patients with oncological and non-oncological diseases whose medical records indicate that their hydration status has been assessed daily during the last days of life, and who have had discussions about the risks and benefits of hydration options.
Measured: Through study completion, an average of 3 months
Number of bereaved relatives of patients with cancer and non-cancer diseases who feel satisfied that the deceased person received support to drink or receive fluids if they so desired.
Number of bereaved relatives of patients with oncological and non-oncological diseases whose medical records indicate that deceased person received support to drink or receive fluids if they so desired.
Measured: Through study completion, an average of 3 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted3 Mar 2026
- Study start27 Jan 2022
- Primary completion30 Jan 2026
- Study completion20 Feb 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Patients in Situation of Last Days of Their LifeStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Prospective
- Enrolment
- 348 participants (actual)
- Target duration
- 3 Days
Sponsor and investigators
- Lead sponsor
- Cudeca Hospice Foundation
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07446673
- Sponsor's protocol ID
- CUDECA FOUNDATION
- Acronym
- CUIDARCUDECA
- Status last verified
- Nov 2025
- First submitted
- 15 Dec 2025
- Last updated
- 3 Mar 2026
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 3 Mar 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Validation and Evaluation of the CUDECA Cui-DAR Plan in People With Oncological and Non-oncological Diseases in the Last Days of Their Lives (CUIDARCUDECA)
- ClinicalTrials.gov ID
- NCT07446673
- Acronym / sponsor ID
- CUIDARCUDECA / CUDECA FOUNDATION
- Keywords
- palliative care, last days of live, care plan, sympton control
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 348 participants (actual)
- Lead sponsor
- Cudeca Hospice FoundationUniversity, hospital or other
- Study start
- 27 Jan 2022 (actual)
- Primary completion
- 30 Jan 2026 (actual)
- Study completion
- 20 Feb 2026 (actual)
- First posted
- 3 Mar 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Cudeca, an independent non-profit organization located in Malaga (Spain), treats patients with advanced and terminal disease. It has developed Cui-DAR Cudeca plan, a care plan for the care of patients in situations of last days of thier live that integrates in a single document, all the assessments and multidisciplinary actions necessary, from the beginning of last days situation, to the care after death. The objective of the study is to evaluate the validity and effectiveness of the Cui-DAR CUDECA Plan in people in a situation of last days compared to conventional care in the assessment of symptoms and signs.
Detailed description
Cudeca, an independent non-profit organization located in Malaga (Spain), treats patients with advanced and terminal disease. It has developed Cui-DAR Cudeca plan, a care plan for the care of patients in situations of last days of thier live that integrates in a single document, all the assessments and multidisciplinary actions necessary, from the beginning of last days situation, to the care after death. It is based on the Liverpool Care Pathway for the Dying Patient created by the Royal Liverpool University Hospital. The objective of the study is to evaluate the validity and effectiveness of the Cui-DAR CUDECA Plan in people in a situation of last days compared to conventional care in the assessment of symptoms and signs. The intervention group will be the patients in the last days of their illness treated at the Cudeca Center with the Cui-DAR Cudeca Plan and those of the control group those treated and deceased in the Palliative Care Unit of the Catalan Institute of Oncology of L'Hospitalet de Llobregat, located in the Duran i Reynals Hospital, which works together with the University Hospital of Bellvitge (Barcelona) and the patients treated in the Palliative Care Unit of San Juan de Dios Hospital in Pamplona (Navarra). In all groups, it will be assessed whether the quality standards recommended by the National Institute for Health and Care Excellence are met: "Care of dying adults in the last days of life", referring to the individualization of care, the anticipatory prescription of drugs and the control of hydration.
Null hypothesis (H0) that will be subjected to contrast in this study is that there are no differences in the assessment of symptoms and signs in patients in a situation of last days, regardless of whether the Cui-DAR CUDECA Plan is applied or not. Piloting will be done on a small sample of patients treated in Hospitalization Unit of CUDECA center.
For the sample calculation, results of national report on the care of people in a situation of imminent death in England have been taken into account.
Authorization of the Ethics Committee of the Costa del Sol District will be requested. The ethical principles established for research on human beings in the Declaration of Helsinki shall be maintained at all times.
Clinical data shall be kept segregated from identification data by means of an alphanumeric code. All registrations will be made respecting the precepts established in the current legislation on the protection of personal data.
Study design
- Observational model
- Case-control
- Time perspective
- Prospective
- Target follow-up
- 3 Days
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Patients who died in the Hospitalization Unit of the Cudeca Foundation (Benalmádena, Málaga,Spain) | – | Other: Care Plan Cui-dar CUdecaPatients in the last days of their illness who die treated in Cudeca,s Inpatient Unit attended with a specific care plan at this situation (Cui-DAR CUDECA Plan) |
| Patients who died in the Catalan Institute of Oncology hospital (Barcelona, Spain) | – | –Patients in the last days of their illness who die treated in the Inpatient Unit of Catalan Institute of Oncology (L'Hospitalet de Llobregat ,Barcelona, España). No intervention. |
| Patients who died in the Inpatient Unit of San Juan de Dios Hospital (Pamplona, Navarra, Spain) | – | –Patients in the last days of their illness who die treated in he Inpatient Unit of San Juan de Dios hospital (Pamplona, Navarra, Spain). No intervention. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients in the last days of life
Key inclusion criteria (3 listed)
- Acceptance to participate in the study by signing the informed consent.
- Patients in the last days of life who die in Cudeca Foundation and who was cared under Cui-DAR Cudeca Plan during data collection period.
- Patients in the last days of life who die in others Palliative care Units Cudeca Foundation and who was cared under Cui-DAR Cudeca Plan durging data collection period.
Key exclusion criteria (3 listed)
- No acceptance to participate in the study by signing the informed consent.
- Patients in the last days of life who die in Cudeca Foundation and who wasn,t cared under Cui-DAR Cudeca Plan during data collection period.
- Pacients
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Care Plan Cui-dar CUdecaAttend to the patient in the last days of their life with the CUi-DAR care plan | Other | Patients who died in the Hospitalization Unit of the Cudeca Foundation (Benalmádena, Málaga,Spain) |
Primary outcome
Number of patients with oncological and non-oncological diseases who are at the end of their lives and have been evaluated with the CUDECA Cui-DAR Plan for the care of symptoms and signs.
Time frame: Through study completion, an average of 12 months
Patients with oncological and non-oncological diseases who die in the Cudeca Foundation Hospitalisation Unit attended with the CUi-DAR Cudeca Plan.
4 secondary outcomes
Number of patients with oncological and non-oncological diseases who has individualised care plans in the last days of life.
Time frame: Through study completion, an average of 3 months
Number of patients with oncological and non-oncological diseases who are at the end of their lives and have been given an advance prescription for medication.
Time frame: Through study completion, an average of 3 months
Number of patients with oncological and non-oncological diseases with daily assessment of hydration at the end of life
Time frame: Through study completion, an average of 3 months
Number of bereaved relatives of patients with cancer and non-cancer diseases who feel satisfied that the deceased person received support to drink or receive fluids if they so desired.
Time frame: Through study completion, an average of 3 months
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 3 Mar 2026.
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
3 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Patients in Situation of Last Days of Their Life and Oncological and no Onoclogical Disease, run by Cudeca Hospice Foundation at 3 sites in Spain.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 3 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 3 sites in Spain. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Number of patients with oncological and non-oncological diseases who are at the end of their lives and have been evaluated with the CUDECA Cui-DAR Plan for the care of symptoms and signs. (time frame: Through study completion, an average of 12 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Mar 2026.